Top Page
Hansa Biopharma AB
(HNSA)
Hansa Biopharma AB (HNSA) vs. iShares MSCI Sweden ETF (EWD)
Hansa Biopharma AB Business Overview & Revenue Model
Hansa Biopharma AB Earnings Call Summary
Hansa Biopharma AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 181.68M | 171.32M | 134.09M | 154.53M | 33.88M | 6.10M |
| Gross Profit | 95.76M | 87.76M | 70.95M | 116.05M | 18.45M | 5.10M |
| EBITDA | -475.42M | -642.07M | -714.55M | -554.26M | -538.83M | -413.08M |
| Net Income | -625.24M | -807.24M | -831.72M | -611.13M | -548.28M | -420.85M |
Balance Sheet | ||||||
| Total Assets | 705.25M | 800.64M | 1.02B | 1.69B | 1.01B | 1.43B |
| Cash, Cash Equivalents and Short-Term Investments | 250.20M | 405.28M | 732.06M | 1.50B | 888.96M | 1.38B |
| Total Debt | 1.02B | 1.08B | 866.77M | 791.09M | 35.38M | 5.04M |
| Total Liabilities | 1.33B | 1.39B | 1.19B | 1.08B | 255.24M | 192.37M |
| Stockholders Equity | -623.74M | -589.83M | -167.88M | 602.91M | 757.57M | 1.24B |
Cash Flow | ||||||
| Free Cash Flow | -697.28M | -675.00M | -755.94M | -506.06M | -483.57M | -290.57M |
| Operating Cash Flow | -696.65M | -674.88M | -755.65M | -502.73M | -481.17M | -290.27M |
| Investing Cash Flow | -628.00K | -116.00K | -284.00K | 229.31M | -2.40M | 182.53M |
| Financing Cash Flow | 406.40M | 346.81M | -7.54M | 1.12B | -4.86M | 1.07B |
Hansa Biopharma AB Technical Analysis
Hansa Biopharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.34B | -0.07 | -63.86% | 2.34% | 16.17% | 0.23% | |
44 Neutral | kr2.21B | ― | ― | 20.12% | 40.54% | ||
| ― | $249.46M | ― | -45.80% | ― | ― | ― | |
| ― | €96.77M | ― | -48.22% | ― | ― | ― | |
| ― | €108.31M | 4.47 | 152.78% | ― | ― | ― | |
| ― | €162.65M | ― | -40.15% | ― | ― | ― | |
| ― | €169.57M | ― | -42.24% | ― | ― | ― |
Hansa Biopharma AB Corporate Events
Hansa Biopharma announced a successful capital raise of approximately 232 MSEK/US $24.3M and restructured its debt with NovaQuest, which will support upcoming Phase 3 trial readouts. The company’s IDEFIRIX product sales increased by 76% compared to the previous year, highlighting strong market performance. Additionally, Hansa appointed Maria Törnsén as COO and President U.S., and Dr. Richard Philipson as Chief Medical Officer, strengthening its leadership team. The company remains on track with its clinical pipeline, including a pivotal Phase 3 trial in kidney transplantation and trials in Guillain Barré Syndrome and Duchenne Muscular Dystrophy.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer, effective July 14, 2025. Dr. Philipson brings over 25 years of experience in drug development, particularly in rare diseases and gene therapy, and will play a crucial role in advancing Hansa’s development programs and regulatory submissions. His expertise is expected to enhance the company’s strategic development plans and strengthen its position in the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced it will release its interim report for the first half of 2025 on July 17, 2025, followed by a conference call to discuss the results and provide a business and pipeline update. This event, featuring key company executives, is an opportunity for stakeholders to gain insights into Hansa’s operational progress and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has presented positive five-year follow-up results from its study on imlifidase in kidney transplantation at the ESOT Congress 2025. The study demonstrated sustained positive outcomes, with a 90% patient survival rate and 82% graft survival rate, indicating that imlifidase is a viable option for highly sensitized patients, providing long-term benefits comparable to standard kidney transplants.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK143.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has announced an increase in its registered share capital and number of shares and votes, following the issuance of new ordinary shares and a set-off issue. This development raises the company’s total number of registered shares and votes to 84,763,222, reflecting a strengthened capital position that could enhance its operational capabilities and market presence.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB held its Annual General Meeting where several key resolutions were passed, including the adoption of financial statements, re-election of board members, and approval of a long-term incentive program for employees. The meeting also authorized the board to issue new shares and warrants, providing the company with financial flexibility to pursue strategic opportunities and enhance shareholder value.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has successfully completed a directed cash share issue, raising approximately SEK 232 million, and has restructured its debt agreement with NovaQuest. This financial maneuver aims to support the company’s ongoing phase III trials for imlifidase and other pipeline projects, positioning Hansa for sustainable growth and strengthening its shareholder base. The restructuring of the NovaQuest agreement includes a set-off issue of USD 14.9 million in new shares and revised payment terms, which are expected to enhance the company’s financial flexibility and operational stability.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB has announced a directed share issue of approximately 10 million common shares to institutional investors, with the proceeds intended for general corporate purposes, including ongoing phase III trials for imlifidase and supporting its European business operations. Additionally, the company is restructuring its debt with NovaQuest, which includes a set-off of USD 14.9 million of debt in exchange for new shares, and revised payment terms extending mandatory cash payments until June 2027. This strategic financial maneuver aims to strengthen Hansa’s capital structure and enhance its operational capabilities, positioning the company for continued growth and stability in the competitive biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will speak at the BIO International Convention in Boston, focusing on unlocking investment opportunities in European biotech. This participation highlights Hansa’s strategic efforts to engage with potential investors and stakeholders, potentially enhancing its industry positioning and expanding its market reach.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced a virtual investor event on Guillain-Barré syndrome (GBS) scheduled for June 16, 2025. The event will feature presentations from renowned medical professionals discussing the current treatment landscape and scientific advancements in GBS. Company executives will also outline Hansa’s activities and milestones in the autoimmune space. This event is part of a series aimed at the investor community, focusing on Hansa’s key areas of interest: Autoimmune, Gene Therapy, and Kidney Transplantation.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB announced a restructuring plan aimed at optimizing resource allocation and improving operational efficiency, which includes a 20% workforce reduction. This strategic move is expected to save 40-50 MSEK annually and enhance the company’s ability to deliver value to shareholders and patients, pending negotiations with trade unions.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB has announced its Annual General Meeting scheduled for June 25, 2025, in Lund, Sweden. The meeting will cover various agenda items including the presentation of financial statements, election of board members, and proposals for a long-term incentive program. This meeting is crucial for stakeholders as it will address key corporate governance issues and strategic decisions that could impact the company’s future direction and market positioning.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma presented promising data from its Phase 2 study of imlifidase at the 2025 PNS Annual Meeting, highlighting its potential in treating Guillain-Barré Syndrome (GBS). The study demonstrated that imlifidase, when used with standard intravenous immunoglobulin, was safe and well-tolerated, offering significant insights into improving patient care for GBS, a condition with limited treatment options.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has appointed Maria Törnsén as Chief Operating Officer and President U.S., effective May 19, 2025. With over 20 years of experience in global and U.S. operations, Törnsén’s expertise in rare diseases and gene therapy is expected to drive the company’s growth and profitability, particularly in the U.S. market. Her appointment comes as Hansa prepares for the next phase of development, including the growth of its IDEFIRIX product and anticipated catalysts in late 2025.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.